Latest News

According to a phase 2 trial, ruxolitinib therapy was associated with improvement in patient-reported outcomes, low non-relapse mortality, and high failure-free survival among patients with refractory sclerotic chronic GVHD.

Results from the phase 2 KUNPENG trial demonstrated that vebreltinib showed promising efficacy and safety among patients with locally advanced or metastatic METex14-mutant non-small cell lung cancer.

According to results from the phase 1/2 BTCRC-LUN17-127 trial, plinabulin plus nivolumab and ipilimumab was well tolerated among patients with recurrent small cell lung cancer, but demonstrated limited clinical benefit.

According to 5-year exploratory data from the IMbrella A study, atezolizumab plus chemotherapy demonstrated promising long-term overall survival results in a cohort of patients with extensive-stage small-cell lung cancer who rolled over from...

There were no differences found for progression-free survival, overall survival, or surgical complications between minimally invasive or open staging surgeries among patients with non-endometrioid endometrial cancer.

According to a prospective longitudinal study, the perceived presence of social support for patients with endometrial who underwent surgery was associated with better quality of life at 1 year post-surgery.

Interim analysis results from the phase 3 AtTEnd trial demonstrated that atezolizumab plus chemotherapy improved progression-free survival among patients with advanced or recurrent endometrial cancer.

The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.

According to results from the TROPiCS-03 study, sacituzumab govitecan showed promising efficacy and manageable safety among patients with heavily pretreated advanced or metastatic endometrial cancer.

The FDA has approved durvalumab plus a platinum-containing regimen followed by surgery and single-agent durvalumab for adult patients with resectable non-small cell lung cancer with no known EGFR mutations or ALK rearrangements.